Tau protiens

Reading File

Finding Sources

Searching the Web

tau protein structure function tauopathies neuroscience 2025

Finding Sources

Searching PubMed

"tau protein" tauopathy neurodegeneration

Reading File

Loading Image

Finding Sources

Reading File

Loading Image

Finding Sources

Here is a thorough overview of tau proteins, drawing from multiple authoritative medical textbooks:

Tau Proteins: A Complete Overview

1. What is Tau?

Tau is a microtubule-associated protein (MAP) encoded by the MAPT gene (Microtubule-Associated Protein Tau), located on chromosome 17. It is expressed abundantly in neurons of the brain, primarily in axons. Its core physiological role is to promote the assembly and stability of microtubules, which form the internal scaffolding of neurons and serve as tracks for axonal transport.

In axons, tau binds along the length of microtubules, compressing and stabilizing them
In dendrites, the analogous function is performed by MAP2
Tau also regulates axonal transport via motor proteins (dynein and kinesin)
Additional roles include synaptic plasticity, nuclear DNA/chromatin protection from oxidative stress, and intracellular signaling

"Tau is a microtubule-associated protein expressed abundantly in neurons of the brain. Hyperphosphorylated forms of tau compose the neurofibrillary tangles." - Thompson & Thompson Genetics in Medicine

2. Structure and Isoforms

Tau exists as multiple isoforms produced by alternative mRNA splicing of the MAPT gene. The most clinically important distinction is between:

Isoform	Microtubule-Binding Domains	Notes
3R tau	3 repeats	Equal with 4R in healthy adult brain
4R tau	4 repeats	Slightly stronger microtubule binding

The balance between 3R and 4R isoforms is critical for normal neuronal function. Disturbances in this ratio provoke tau aggregation and disease.

MAPT gene mutations alter the ratio of tau 3R and 4R isoforms, leading to pathological tau accumulation

Mutations in the MAPT gene alter the ratio of 3R and 4R tau isoforms, leading to pathological aggregation. (Stahl's Essential Psychopharmacology)

3. Phosphorylation - The Key Regulatory Switch

Tau's binding to microtubules is regulated by phosphorylation. There is an inverse relationship between phosphorylation and microtubule binding:

Normal tau: low phosphorylation → stable microtubule binding
Hyperphosphorylated tau: detaches from microtubules → aggregates → forms neurofibrillary tangles (NFTs)
Key kinases involved include GSK-3β (glycogen synthase kinase-3 beta) and CDK5

When tau hyperphosphorylates, it can no longer perform its stabilizing function. The resulting loss of microtubule integrity disrupts axonal transport, causing axons to wither and synaptic connections to be lost.

4. Neurofibrillary Tangles (NFTs)

NFTs are the pathological hallmark of tau disease:

Structurally, they consist of paired helical filaments (PHFs) - two tau strands braided together like rope
They form inside neurons (intracellular), in contrast to amyloid plaques which are extracellular
Under silver staining (Bielschowsky method) or tau immunohistochemistry, they appear as dark inclusions within neuronal cytoplasm
Neurons with heavy tangle burden eventually die, leaving only the tangle as a "tombstone"

"The severity of the dementia in Alzheimer's disease is well correlated with the number and distribution of neurofibrillary tangles, the 'tombstones' of dead and dying neurons." - Neuroscience: Exploring the Brain, 5th Ed.

Normal neurons vs Alzheimer's disease neurons showing neurofibrillary tangles and amyloid plaques

Left: Normal neurons. Right: Alzheimer's disease with neurofibrillary tangles (intraneuronal, red/green coils) and amyloid plaques (extracellular, red clusters). (Neuroscience: Exploring the Brain, 5th Ed.)

5. Tauopathies - Diseases Caused by Tau Pathology

Any disease characterized by abnormal tau accumulation is called a tauopathy. They are classified by the predominant isoform involved:

Primary Tauopathies (tau alone, no amyloid)

Disease	Tau Type	Key Features
Pick's Disease	3R tau	Knife-edge frontal/temporal atrophy; Pick bodies (round tau inclusions) in neurons
Progressive Supranuclear Palsy (PSP)	4R tau	Vertical gaze palsy, falls, parkinsonism
Corticobasal Degeneration (CBD)	4R tau	Asymmetric limb apraxia, alien limb
FTLD-tau	3R or 4R	Frontotemporal lobar degeneration due to MAPT mutations
Chronic Traumatic Encephalopathy (CTE)	3R+4R	Head trauma history; perivascular tau deposits

Secondary Tauopathies (tau + other pathology)

Disease	Notes
Alzheimer's disease (AD)	NFTs + amyloid plaques; tau burden mirrors dementia severity
Down Syndrome	NFTs appear early; similar to AD
Dementia pugilistica	Punch-drunk syndrome; also has NFTs

MAPT Gene Mutations in FTLD-tau

Two types of MAPT mutations are described (Robbins & Kumar):

Missense point mutations - affect tau phosphorylation, tipping balance toward aggregation
Splicing mutations (often intronic) - alter 3R:4R ratio, also promoting aggregation

There is both a loss-of-function component (tau depleted from microtubules) and a toxic gain-of-function component (aberrant aggregated tau).

6. Tau in Alzheimer's Disease

In AD, tau pathology follows a predictable anatomical progression (Braak staging):

Early stages: NFTs in entorhinal cortex and hippocampus → episodic memory loss (mild cognitive impairment)
Intermediate: Spreads to association cortices of frontal, parietal, temporal lobes
Late/severe: NFTs reach occipital lobes and primary motor/sensory cortices

NFTs appear in the medial temporal lobe and brainstem even in cognitively normal people in their 40s
Tangle spread is thought to occur via transsynaptic propagation (prion-like spread)
Unlike amyloid plaques (which plateau early), NFT burden closely mirrors dementia severity

The amyloid cascade hypothesis proposes: Aβ accumulation → triggers tau hyperphosphorylation → NFT formation → synaptic failure → neuronal death.

7. Tau as a Biomarker

CSF tau is one of the most validated biomarkers in neurology:

Biomarker	What it measures	In AD
T-tau (total tau)	Overall neuronal/axonal damage	Elevated
P-tau181 (phospho-tau)	Specific AD-related phosphorylation	Elevated (high specificity for AD)
CSF Aβ42/tau ratio	Combined amyloid + tau	Reduced ratio = AD pattern

The combination of low CSF Aβ42 + elevated CSF tau has ~85% sensitivity and ~86% specificity for AD diagnosis (Bradley & Daroff's Neurology).

Harrison's Principles of Internal Medicine (2025) classifies plasma Aβ and p-Tau as "core 1 biomarkers" - necessary and sufficient for AD diagnosis regardless of symptoms. Tau PET imaging is a "core 2 biomarker" for further staging.

8. Therapeutic Targets

Current research targets include (Stahl's Psychopharmacology):

Strategy	Approach
Anti-tau antibodies	Active immunization against pathological tau
Tau aggregation inhibitors	Block filament formation
Tau phosphorylation inhibitors	Inhibit GSK-3β and other kinases
Microtubule stabilizers	Compensate for tau loss-of-function

Summary

Tau is a neuronal scaffolding protein that keeps axonal microtubules stable. When it becomes hyperphosphorylated, it detaches, aggregates into paired helical filaments, and forms neurofibrillary tangles that kill neurons. The disease burden from tau - in Alzheimer's, FTD, PSP, Pick's, and other tauopathies - is one of the major unsolved challenges in neurodegeneration research. CSF and plasma tau biomarkers are now central to clinical diagnosis of these conditions.

Sources: Stahl's Essential Psychopharmacology | Thompson & Thompson Genetics in Medicine, 9th Ed. | Robbins, Cotran & Kumar Pathologic Basis of Disease | Neuroscience: Exploring the Brain, 5th Ed. | Goldman-Cecil Medicine | Bradley & Daroff's Neurology in Clinical Practice | Harrison's Principles of Internal Medicine 22E (2025)

This is a shared conversation. Sign in to Orris to start your own chat.